Last reviewed · How we verify
Neodolpasse
Neodolpasse, marketed by the Medical University of Vienna, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging the protection of its key patent. The primary risk is the potential increase in competition post-2028, as generic versions may enter the market upon patent expiration.
At a glance
| Generic name | Neodolpasse |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia (NA)
- Neodolpasse® Infusion Solution Versus Diclofenac 75 mg Infusion in the Treatment of Postoperative Pain After Elective Knee Surgery (PHASE4)
- Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neodolpasse CI brief — competitive landscape report
- Neodolpasse updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI